Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 2011. The report details a specific share repurchase transaction executed on October 27, 2011, in accordance with shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 900,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,409.0 pence per share; lowest price paid was 1,368.5 pence per share.
- Treasury Holdings (Settled): 508,714,248 shares (9.13% of total issued share capital).
- Treasury Holdings (Including Unsettled): 510,189,248 shares (10.08% of current total voting rights).
- Shares in Issue (Excluding Treasury): 5,062,882,567 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 900,000 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 10.08% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. It is a compliance disclosure regarding share buybacks under the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (508,714,248 settled) against the company's latest capitalization table.
- Confirm the calculation of total voting rights (5,062,882,567 shares in issue) for disclosure threshold notifications.
- Review the price paid per share (1,368.5 to 1,409.0 pence) relative to the market price on October 27, 2011.
- Note that this filing does not contain financial performance data; refer to Form 20-F for comprehensive financial results.